DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,074 filers reported holding DANAHER CORPORATION in Q4 2022. The put-call ratio across all filers is 1.10 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $724,700 | +3.3% | 2,921 | -0.0% | 0.09% | +4.8% |
| Q2 2023 | $701,280 | -3.6% | 2,922 | +1.2% | 0.08% | -16.2% |
| Q1 2023 | $727,387 | -6.5% | 2,886 | -1.5% | 0.10% | -12.4% |
| Q4 2022 | $777,681 | +4.4% | 2,930 | +1.5% | 0.11% | -11.7% |
| Q3 2022 | $745,000 | -0.5% | 2,886 | -2.3% | 0.13% | +2.4% |
| Q2 2022 | $749,000 | -13.2% | 2,955 | +0.4% | 0.12% | -22.4% |
| Q1 2022 | $863,000 | -15.1% | 2,942 | -4.8% | 0.16% | -3.0% |
| Q4 2021 | $1,017,000 | +5.4% | 3,090 | -2.6% | 0.17% | -22.4% |
| Q3 2021 | $965,000 | +16.5% | 3,171 | +2.8% | 0.21% | +6.5% |
| Q2 2021 | $828,000 | +414.3% | 3,086 | +331.6% | 0.20% | +356.8% |
| Q1 2021 | $161,000 | +136.8% | 715 | +132.1% | 0.04% | +109.5% |
| Q4 2020 | $68,000 | -82.4% | 308 | -82.8% | 0.02% | -84.6% |
| Q3 2020 | $387,000 | +26.1% | 1,795 | +3.5% | 0.14% | +11.5% |
| Q2 2020 | $307,000 | +30.1% | 1,734 | +1.6% | 0.12% | +13.0% |
| Q1 2020 | $236,000 | -12.3% | 1,706 | -2.7% | 0.11% | +14.9% |
| Q4 2019 | $269,000 | -35.2% | 1,754 | -39.0% | 0.09% | -22.3% |
| Q3 2019 | $415,000 | +56.0% | 2,875 | +54.3% | 0.12% | +47.6% |
| Q2 2019 | $266,000 | +16.2% | 1,863 | +7.6% | 0.08% | +15.5% |
| Q1 2019 | $229,000 | +27.9% | 1,731 | -0.3% | 0.07% | +14.5% |
| Q4 2018 | $179,000 | -5.3% | 1,736 | -0.2% | 0.06% | +1.6% |
| Q3 2018 | $189,000 | -8.3% | 1,739 | -16.5% | 0.06% | -41.3% |
| Q2 2018 | $206,000 | -9.3% | 2,083 | -10.2% | 0.10% | -15.4% |
| Q1 2018 | $227,000 | +6.1% | 2,320 | +0.4% | 0.12% | +3.4% |
| Q4 2017 | $214,000 | +7.5% | 2,310 | -0.5% | 0.12% | +0.8% |
| Q3 2017 | $199,000 | +1.5% | 2,322 | -0.2% | 0.12% | -4.1% |
| Q2 2017 | $196,000 | +7.1% | 2,327 | +8.7% | 0.12% | +11.8% |
| Q1 2017 | $183,000 | +13.7% | 2,140 | +3.2% | 0.11% | +10.0% |
| Q4 2016 | $161,000 | -1.2% | 2,073 | -0.0% | 0.10% | -9.1% |
| Q3 2016 | $163,000 | -20.5% | 2,074 | +2.2% | 0.11% | -25.7% |
| Q2 2016 | $205,000 | +9.6% | 2,029 | +3.1% | 0.15% | +2.8% |
| Q1 2016 | $187,000 | -7.4% | 1,968 | -9.4% | 0.14% | -5.3% |
| Q4 2015 | $202,000 | +9.2% | 2,173 | -0.1% | 0.15% | +4.1% |
| Q3 2015 | $185,000 | -1.6% | 2,176 | -0.9% | 0.15% | +9.0% |
| Q2 2015 | $188,000 | 0.0% | 2,196 | -1.0% | 0.13% | +2.3% |
| Q1 2015 | $188,000 | -1.1% | 2,218 | 0.0% | 0.13% | -6.4% |
| Q4 2014 | $190,000 | +555.2% | 2,218 | +485.2% | 0.14% | +460.0% |
| Q3 2014 | $29,000 | +11.5% | 379 | +14.5% | 0.02% | +8.7% |
| Q2 2014 | $26,000 | -54.4% | 331 | -55.2% | 0.02% | -28.1% |
| Q4 2013 | $57,000 | – | 739 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |